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1. Introduction
Rubinstein–Taybi syndrome (RSTS) is a congenital dis-
order. The associated symptoms described earlier by 
Michail et al. (1957) were precisely delineated later as a 
syndrome by Rubinstein and Taybi (1963). Broad, angulated 
thumbs and halluces are considered to be the hallmark of 
the syndrome. Other specifi c symptoms include growth and 
mental retardation, and a wide range of dysmorphic features 
and skeletal abnormalities. Mutations and chromosomal 
rearrangements in the gene encoding the CREB-binding 
protein (CREBBP/CBP) located on 16p13.3 are reported 
to be the causative lesions in several cases of RSTS
(Petrij et al. 1995, 2000b; Giles et al. 1997), although a total 
association with pathogenic mutations in CREBBP has not 
been reported.
Human CREBBP is a nuclear protein consisting of 
2442 amino acids; predicted domains include the nuclear 
receptor-binding and receptor-interacting domain (NHRD, 
aa 1–170), the amino-terminal transactivation domain 
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(NTAD, aa 228–461), the Cys/His-rich region 1 (CH1, aa 
363–496), the CREB-binding domain (KIX, aa 452–682), 
the bromo domain (BROMO/BRD, aa 1108–1170), the 
histone acetyltransferase domain (HAT, aa 1173–1849), Cys/
His-rich region 2 (CH2, aa 1232–1487), Cys/His-rich region 
3 (CH3, aa 1690–1860) and the C-terminal transactivation 
domain (CTAD, aa 1960–2162) (Bentivegna et al. 2006). 
CREBBP was fi rst identifi ed as a transcriptional co-activator 
for the cyclic AMP response element (CRE)-binding protein 
CREB (Chrivia et al. 1993) that mediates the genomic 
effects of cAMP by binding to CRE elements on DNA. 
CREBBP functions by transactivating CREB-regulated 
transcription when bound to CREB via its KIX domain 
(Murata et al. 2001). The nuclear hormone receptor-binding 
domain (NHRD) is the region for interaction with the 
nuclear hormone receptors that represent ligand-dependent 
transcription factors and regulate target genes involved in cell 
growth and differentiation. NTAD and CTAD are the N- and 
C-terminal transactivation domains of the protein, while the 
BROMO domain interacts with acetylated lysine and other 
proteins. The HAT domain is essential for acetyltransferase 
activity which catalyses the acetylation of all four core 
histones and of several non-histone nuclear proteins, while 
the three CH domains in the protein serve as docking 
sites for several transcription factors and also mediate 
protein–protein interactions (Goodman and Smolik 2000). 
The CREBBP protein thus plays a critical role in complex 
biological processes during development. Effectively, 
mutations in this gene and abnormal functioning of the 
protein can lead to aberrant patterns in lineage development 
during embryonic development. Some symptoms of the 
RSTS syndrome are believed to emerge from such defects in 
development (Roelfsema et al. 2005). 
The aim of the present study was to identify the rate
of point mutations and other molecular lesions in
CREBBP among true RSTS patients in the Indian
population. To the best of our knowledge, no such analysis 
has been done, nor is any information available on the 
occurrence of single-nucleotide polymorphisms (SNPs) 
in the CREBBP gene. A salient feature of this study is the 
highest detection rate of CREBBP mutations (76.9%) in 
RSTS patients to date, of which 10 are predicted to be 
pathogenic and three were identifi ed to be critical for histone 
acetyltransferase activity. Linkage disequilibrium studies 
revealed an association of CREBBP polymorphisms with 
disease susceptibility.
2. Materials and methods
2.1 Clinical material
The Institutional Bio-Ethics Committee at NCCS, Pune 
approved the present study and informed written consent 
was obtained from all patients. In case of minor patients 
(age less than 18 years), written consent was obtained
from their parents. Patients with RSTS (N=13) were 
identifi ed by clinical geneticists, based on the presentation 
of the classical symptoms known to be associated with
this syndrome (supplementary table 1). The main facial 
features observed in the patients included heavy and 
arched eyebrows, long eyelashes, strabismus, nasolacrimal 
duct obstruction, myopia/cataracts/glaucoma/coloboma, 
downward slanting palpebral fi ssures, large nose, convex/
beaked profi le of the nose, narrow palate, micrognathia, and 
low-set ears, which are considered to be classical symptoms 
(Dai et al. 1999). Accordingly, we classifi ed 11/13 (84.6%) 
patients included in our study as classical/typical RSTS 
patients. Within this patient cohort, the sex ratio (female: 
male) was 5:8. 
All patients also showed mild to severe psychomotor/
mental retardation. Microcephaly was present in 12/13 
patients. Skeletal abnormalities such as the typical large 
thumb were evident in 11/13 (84.6%); radially deviated 
thumbs were also observed at the same frequency. Patients 4 
and 6 (RSTS4a and RSTS6a) who did not have broad thumbs 
had radially deviated thumbs. Thus, thumb abnormality was 
present in the entire patient cohort. 
Peripheral blood samples were collected from the above 
patients as well as their parents (whenever available) and 
100 randomly selected healthy controls. All samples were 
used for genomic DNA isolation using the Qiagen FlexiGene 
DNA kit (Qiagen, USA).
2.2 Polymerase chain reaction amplifi cation, DNA
sequencing and mutational analysis
The 31 exons of the CREBBP gene were amplifi ed from 
genomic DNA by polymerase chain reaction (PCR). Primers 
were designed to amplify all the coding exons and intron/
exon (I/E) boundaries (supplementary table 2) except exon 
2 where, due to a high guanine–cytosine (GC)-rich region, 
the primers were designed to cover only the exon region. 
The amplifi ed fragments were sequenced using an ABI 3700 
DNA sequencer (Applied Biosystems Inc. USA). Sequences 
thus obtained were subjected to alignment against a 
consensus sequence of the CREBBP (NM_004380) using 
the ABI Seqscape (version 2.0) software; this identifi ed 
mismatches in the nucleotide bases. Re-sequencing was 
done twice in the opposite directions to rule out sequencing 
errors. Likely polymorphic sites were then recorded as 
putative nucleotide changes. In addition, to minimize 
genotyping errors, the measure of non-conformity in the 
samples to Hardy–Weinberg proportion for each nucleotide 
change was calculated, and a deviation from the Hardy–
Weinberg proportion was considered as being indicative of 
sequencing errors.
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2.3 Database mining from existing datasets
Previously identifi ed DNA variants, which include 
point mutations, chromosomal translocations such as 
in-del mutations as well as microdeletions of CREBBP 
reported in public databases including the National 
Center for Biotechnology Information (NCBI; http:
//www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM), SNP 
Consortium Limited (TSC) (http://snp.cshl.org), Institute 
of Medical Science – Japanese Science and Technology 
Japanese SNPs (IMS-JST JSNP) database (http://snp.ims.u-
tokyo.ac.jp), the Ensembl Genome Browser (http:
//www.ensemle.org), GeneSNPs Public Internet (http:
//www.genome.utah.edu/genesnps), and the 1000 genomes 
database (http://browser.1000genomes.org/index.html) 
were used as reference databases to classify the nucleotide 
changes in our study as being either known/novel. 
2.4 Splice site analysis
Splice site analysis was carried out using the NetGene2 
Server, a service producing neural network prediction 
through splice sites in H. sapiens, C. elegans and A. thaliana 
DNA (Hebsgaard et al. 1996).
2.5 Conservation index (CI) analysis
Conservation of mutated amino acids was screened
across 11 species including Caenorhabditis elegans, 
Melanospora aegyptica, Danio rerio, Xenopus tropicalis, 
Gallus gallus, Mus musculus, Rattus norvegicus, Canis 
familiaris, Felis catus, Pan troglodytes and Homo sapiens 
using ClustalW (http://www.ebi.ac.uk/clustalw/). The 
conservation index (CI) was calculated using the following 
formula: 
CI = Frequency of conservation *100
  Total no. of species
where frequency of conservation denotes the number of 
species in which an amino acid is conserved. 
Values of CI <0.5 were construed to be low; values 
ranging between 0.5 and 0.75 were considered as medium, 
and CI values >0.75 were considered to be high.
2.6 SIFT (Sorting Intolerant From Tolerant)
analysis
Prediction of mutation effects was carried out using a web 
program SIFT (http://blocks.fhcrc.org/sift/SIFT.html), which 
utilizes evolutionary information from homologous proteins 
(Ng et al. 2001, 2003).
2.7 Protein estimation and western blotting
Western blotting was performed using standard procedures. 
Briefl y, equal amounts of nuclear proteins extracted 
using a HAT assay kit (#17-289; Upstate Cell Signaling 
solutions. NY, USA) were resolved on 10% SDS-PAGE 
gels and the resolved proteins were transferred to a 
polyvinylidene fl uoride (PVDF) membrane. Blots were 
incubated with 1:1000 dilution of CBP antibody (A22; 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
and the immunoreactive bands were visualized by using the 
Pierce Super Signal West Pico Chemiluminescence system 
(Thermo Fisher Scientifi c, USA). Blots were subsequently 
stripped and E1A binding protein p300 (EP300) was detected 
with a 1:800 dilution of EP300 antibody (C-20; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) as described 
above. Finally, the blots were stripped and developed using a 
1:800 dilution of histone (H1) antibody (FL-219; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA), which was used 
as the loading control.
2.8 Acetyltransferase assays
To test endogenous CREBBP acetyltransferase activity from 
Epstein–Barr virus (EBV)-transformed lymphoblastoid cells 
in vitro, a HAT assay kit (#17-289, Upstate Biotechnology) 
was used according to the manufacturer’s instructions. 
Briefl y, 100 ng of biotinylated histone H4 peptide was 
added per well in streptavidin-coated 96-well microplates. 
After blocking with 3% bovine serum albumin, tested 
compounds diluted in DMSO were added to the wells at the 
indicated concentrations. Acetyl-coenzyme A (100 μmol/l) 
and nuclear extract (50 ng) were then added to a total assay 
volume of 50 μl. The plates were incubated at 30°C for ~8 
min, then washed fi ve times with TBS, and incubated with 
anti-acetyl-lysine antibodies for 1.5 h at room temperature. 
After incubation with horseradish peroxidase-conjugated 
secondary antibodies, 100 μl of the substrate mixture 
was added to each well and incubated for 10 min at room 
temperature. The reaction was terminated with 50 μl of fresh 
1 mol/l sulphuric acid and the plates were read at 450 nm. 
2.9 Phylogenetic analysis
CREBBP variant sequences obtained from RSTS patients 
were applied for constructing phylogenetic trees as described 
earlier (Wani et al. 2006). 
2.10 Haplotype determination
Gevalt 2.0 (GEnotype Visualization and ALgorithmic Tool) 
(Davidovich et al. 2007) was used to determine haplotypes as 
well as haplotype blocks. Gevalt constructs haplotypes using 
an accelerated expectation maximization algorithm similar to 
the partition/ligation method (Qin et al. 2002), which creates 
highly accurate population frequency estimates of the phased 
haplotypes based on the maximum likelihood derived from 
the unphased input genotypes (genotype resolution and block 
identifi cation using likelihood [GERBIL]). Gevalt employs 
the Li–Stephens model (Li and Stephens 2003), which 
simulates case and control individuals conditional upon a set 
of known haplotype data using an estimate of the fi ne-scale 
recombination rate across a region. This analysis is preferable 
to a direct resampling approach (de Bakker et al. 2005) which 
produces new haplotypes that are copies of the original 
HapMap haplotypes. Even if there is a modest amount of 
overfi tting in the reported power levels, because of the same 
simulated datasets the qualitative differences between the 
performances of the two methods remain the same.
The test for association is usually based on the difference 
in allele frequency between case and control individuals. 
For a single SNP, a common test suggested by Olson and 
Wijsman (1994) is based on building a contingency table of 
alleles compared with disease phenotypes (i.e. case/control) 
and then calculating a -χ2 distributed statistic. When multiple 
markers in a chromosomal region are to be tested, several 
studies suggest the use of generalized linear models (Schaid 
et al. 2002; Zaykin et al. 2002; Lin 2006). Such methods must 
assume a specifi c distribution of the trait, given the SNPs, 
and this assumption does not always hold true. Typically, a 
Bonferroni correction for the P value is employed to account 
for multiple testing. However, this correction does not take 
into account the dependence of strongly linked marker loci 
and may lead to overconservative conclusions. This problem 
worsens when the number of sites increases. Thus, to address 
these diffi culties, Zhang et al. (2002) suggested a Monte 
Carlo procedure (Kalos 1986) to evaluate the overall P value 
of the association between the SNP data and the disease: 
the χ2 value of each marker is calculated, and the maximum 
value over all markers, denoted by CC
max
, is used as the test 
statistic. The same statistic is calculated for many datasets 
with the same genotypes and with randomly permuted labels 
of case and control individuals. The fraction of permutations 
for which this value exceeds the original CC
max
 is used as 
the P value. A clear advantage of this test is that no specifi c 
distribution function is assumed. Additionally, the test 
handles multiple testing directly and avoids correction bias. 
Gevalt uses the same principle and hence P values were not 
additionally corrected using Bonferroni correction. 
Accordingly, linkage disequilibrium (the D’ statistic) 
was calculated between each pair-wise combination of all 
the mutations and SNPs within the CREBBP gene. Gevalt 
is able to determine haplotype blocks using different block 
partition algorithms (Barrett et al. 2005). In our dataset, the 
solid spine method of the linkage disequilibrium algorithm 
was used to determine the haplotype blocks within the 
CREBBP gene. Haplotypes within each block were assigned 
to individual subjects only when the assignment could 
be made with a greater than 95% certainty. Markers with 
D’ values = 1 were selected as these were in complete 
linkage disequilibrium and were not separated as a result of 
recombination events. This resulted in the identifi cation of 
eight groups showing markers of independent association or 
interdependency (supplementary table 3). These groups of 
markers were further analysed to identify an increased level 
of stringency of correlation with disease susceptibility, i.e. 
those markers were selected whose r2 values were equal to 
one. This fi nally led to the identifi cation of the two groups as 
discussed in detail in the Results section.
2.11 Statistical analysis
RSTS patient and control data were analysed using a χ2 
test. The gene counting method estimated allele frequencies 
for all the genotyped polymorphisms and the χ2 test was 
used to identify deviation from Hardy–Weinberg (HW) 
proportions.
3. Results
3.1 Nucleotide variations in CREBBP in RSTS patients
Screening for nucleotide changes by direct sequencing of 31 
PCR genomic fragments encompassing the complete coding 
sequence and splice sites of the CREBBP gene in the 13 
Indian RSTS patients led to the identifi cation of 45 sequence 
alterations (fi gure 1; supplementary tables 4 and 5). Of these, 
25 nucleotide changes were located in the exon regions, 
while the remaining 20 were either in intron or I/E boundary 
regions (supplementary fi gure 1; supplementary tables 4, 5). 
All the exon changes were novel and have not been reported 
previously; 18 of these were missense while seven did 
not result in an altered amino acid (i.e. were sense/silent) 
(fi gure 2A). Further, seven of the 18 missense mutations 
were construed to be de novo mutations since they were not 
identifi ed either in the parents or the controls. The remaining 
11 mutations, although novel, could not be established as 
being either de novo or inherited, as parent samples of the 
patients carrying these mutations were unavailable.
Of the seven silent mutations , changes in amino acid 424, i.e. 
p.Arg424Arg identifi ed in our study, may be critical in RSTS 
as a nonsense mutation in the same amino acid generating 
a stop codon (p.Arg424X) has been reported earlier and 
considered to be pathogenic due to the formation of a truncated 
CREBBP protein (Bartsch et al. 2002; Bartsch et al. 2005). 
The remaining six silent mutations are novel; three of these 
were identifi ed as being de novo. Among the 20 intron or I/E 
boundary nucleotide changes, g.18617C>G (c.3982+93C>G; 
rs129974) and g.51363T>G (c.2158+81T>G; rs130002) are 
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known SNPs, six arose de novo, while the remaining were 
novel changes that were not detected in the control samples 
and may contribute to the syndrome.
Fifteen nucleotide changes common to patients as well 
as parents were identifi ed (supplementary table 6). One 
of these was present in the exon region and is novel but 
silent (p.His1235His); the remaining 14 were located at I/E 
boundaries and were neither present in the controls nor have 
they been reported earlier. Besides the patient-exclusive 
and patient–parent common nucleotide changes, four novel 
variants were also identifi ed in the intron regions only in the 
parents (supplementary table 7). 
3.2 Domain-wise distribution of mutations
The overall pattern of distribution of nucleotide changes in 
the CREBBP gene identifi ed in our Indian RSTS patients 
initially appeared to be similar to that reported in the 
existing database (Bartsch et al. 2002, 2005; Coupry et 
al. 2002; Kalkhoven et al. 2003; Roelfsema et al. 2005; 
Udaka et al. 2005; Bentivegna et al. 2006) (supplementary 
table 10). Further analysis revealed a distinctive signature 
of distribution in our study. A majority of the exon and I/E 
variants identifi ed in previous studies (fi gure 2B) are located 
in the domains of HAT (44.7%), CH2 (15%), CH1 (13.1%), 
and NTAD (8.1 %), while variants in the other domains, viz. 
NHRD, CREB, BROMO, CH3 and CTAD (together 16.4%) 
were very few. Our study in Indian patients identifi ed a 
maximum number of exon- and I/E-localized nucleotide 
changes (fi gure 2C) in the HAT (42.2%) followed by CREB 
(15.5%), CH1 (13.3%), CH2 (13.3%) and CH3 (6.6%) 
domains (fi gure 2C), while the frequency of variants in 
the NHRD, NTAD, BROMO and CTAD regions was very 
low (together 8.8%). Distinct differences were seen in the 
frequency of variants lying in the CREB domain (15.5% vs 
J. Biosci. 35(2), June 2010
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Figure 1. Representation of the distribution of nucleotide changes in the CREBBP gene of RSTS patients and their parents. Numbers in 
each block represent the number of mutations in the same group. As is the convention, exon mutations/SNPs causing amino acid changes 
were classifi ed as missense/non-synonymous, while those that translated into the same amino acid were termed silent/synonymous. Those 
variants which were present exclusively in the patients and not in the parents were considered to have arisen de novo; those which were 
not found either in the parents, controls or in the dbSNP database were referred to as novel. Nucleotide changes found in controls alone or 
listed in the dbSNP were classifi ed as SNPs.
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5.8% in the database and Indian RSTS patients, respectively). 
The CH-rich regions also revealed nucleotide changes 
between the database and Indian RSTS patients (28% vs. 
33.2%, respectively). The highest degree of nucleotide 
change was evident in the CH3 region between the database 
and Indian RSTS patients ((0 vs 13.3%, respectively; fi gure 
2 B, 2C). 
A similar pattern was also evident in the exclusive 
distribution of exon mutations in RSTS patients (fi gure 3A). 
The existing database (Bartsch et al. 2002, 2005; Coupry et al. 
2002; Kalkhoven et al. 2003; Roelfsema et al. 2005; Udaka 
et al. 2005; Bentivegna et al. 2006) indicated a distribution 
of exon mutations maximally in the HAT (38.5%) followed 
by the NTAD (12.8%) and CH2 (11.4%) domains, whereas 
in the Indian RSTS patients, we noted that, while a large 
number of mutations were indeed located in the HAT region 
(24%), a majority of the remaining mutations clustered 
around the three zinc fi nger regions, with their frequencies 
being CH1 (24%), CH2 (24%) and CH3 (12%). A signifi cant 
difference in the number of mutations in the NTAD domain 
Figure 2. (A) Location of the exon CREBBP mutations found in this study. Only exons are drawn to scale. Missense mutations are 
in red colour, sense (silent) mutations in blue colour. The domains indicated in the fi gure include the nuclear receptor-binding and 
receptor-interacting domain (NHRD, aa 1–170), the amino-terminal transactivation domain (NTAD, aa 228–461), the Cys/His-rich 
region 1 (CH1, aa 363–496), the CREB-binding domain (CREB /KIX, aa 452–682), the bromo domain (BROMO/BRD, aa 1108–1170), 
the histone acetyltransferase domain (HAT, aa 1173–1849), Cys/His-rich region 2 (CH2, aa 1232–1487), Cys/His-rich region 3 (CH3, 
aa 1690–1860)  and the C-terminal transactivation domain (CTAD, aa 1960–2162). (B) Domain-wise distribution of nucleotide changes 
in the existing database. (C) Domain-wise distribution of nucleotide changes in this study. The domains indicated in the fi gure include 
NHRD, the nuclear receptor-binding and receptor interacting domain; NTAD, the amino-terminal transactivation domain; CH1, fi rst 
zinc fi nger; CREB/KIX, the CREB-binding domain; BROMO, the bromo domain; HAT, the histone acetyltransferase domain;CH2 
and CH3, the second and third zinc fi ngers; CTAD, the C-terminal transactivation domain; ND, regions of the gene not included in 
any domain. The numbers indicate the percentage of mutations identifi ed in the respective domains. A resampling-based approach 
was used to determine the frequencies of distribution so that the frequency of mutations in each domain in our study and the database
are from the same number of individuals.
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was also evident, with those in the database being reported at 
a higher frequency (12.8% as compared to 2% in the Indian 
patients). Thus, the distribution of nucleotide changes in the 
I/E regions as well as exon mutations in the CREBBP gene 
in Indian RSTS patients exhibited a specifi c pattern, with 
the three zinc fi ngers and HAT domain being putative hot 
spots.
3.3 Assessment of the pathogenicity of missense mutations 
in our study
Missense mutations are considered pathogenic when at 
least one of the following features is associated with the 
mutation (Downing et al. 1996; Faivre et al. 2009): (i) de 
novo missense mutation, (ii) missense mutation substituting 
or creating a cysteine, (iii) missense mutation involving 
a consensus calcium-binding residue, (iv) substitution of 
glycines that are implicated in correct domain–domain 
packing, (v) intrafamilial segregation of a missense mutation 
involving a conserved amino acid. These parameters were 
applied towards assessing the pathogenicity of the missense 
mutations in the present study. Thus, the following analyses 
were performed.
3.3.1 Conservation index (CI) analysis: All the missense 
mutations identifi ed in our study as well as those documented 
earlier in the database were analysed on the basis of their 
distribution in the various functional domains of the protein, 
Figure 3. (A) Comparative distribution of exon mutations between the existing database and our study. The exon mutations in the database 
are primarily localized in the HAT domain, whereas in our study they are concentrated in the CH1, CH2, CH3 and HAT domains. *Denotes 
the domains having signifi cant difference (>5%) between database exon mutations and those identifi ed in this study. (B) Distribution of 
missense mutations only in the existing database according to their conservation indices. (C) Distribution of missense mutations in the 
Indian population according to their conservation indices (see also footnotes # and $ of table 2). CREBBP domains are plotted on the X 
axis, CI on the Y axis. M stands for medium conservation whereas H stands for high conservation index.
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as described earlier, and their conservation indices (CIs) 
across 11 species (table 1). Applying a classifi cation of low 
(CI <0.5), medium (CI 0.5–0.75) or high CI (CI >0.75) to 
the CREBBP missense mutations in the existing database, 
some of them were found to be associated with a high CI 
(fi gure 3B), and have been reported to be pathogenic (Murata 
et al. 2001; Coupry et al. 2002; Kalkhoven et al. 2003; 
Bartsch et al. 2005; Roelfsema et al. 2005; Udaka et al. 
2005; Bentivegna et al. 2006); exceptions, however include 
p.Asn1978Ser, p.Ala981Thr, p.Met2221Leu (table 2).
Applying the same analysis to our study, we observed that 
missense mutations in the NHRD and CH1 domains showed 
a medium CI, whereas those localized in the CH2, CH3 
and HAT domains were highly conserved (fi gure 3C). In 
conclusion, the 10 missense mutations identifi ed in our study 
with a CI >0.75 (table 1) could be potentially pathogenic.
3.3.2 SIFT (Sorting Intolerant From Tolerant) analysis: 
The SIFT algorithm predicts the effects of amino acid 
substitution on protein function, based on the position and 
type of amino acid change (Ng et al. 2001). On subjecting 
the missense mutations identifi ed in our study to SIFT 
analysis, we predicted that 13 out of the 18 missense 
mutations were potentially deleterious and may alter protein 
function (table 1). 
3.3.3 Structural changes in the protein structure 
predicted from domain-specifi c mutations: The structure of 
proteins permits a more detailed understanding of mutations 
observed in a number of human disease states. We thus 
Table 1. Distribution of missense mutations in Indian RSTS patients based on their conservation index
No. Mutation  CREBBP 
domain 
Conservation 
across species 
(number)#
Conservation 
index (CI) 
SIFT analysis 
prediction 
SIFT analysis 
prediction level 
(high/ low)
Altered 
HAT
activity 
Pathogenic  
1 p.Asp35Ala NHRD 7 0.64 Affect protein 
function
low ND No 
2 p.Val89Gly NHRD 7 0.64 Tolerated high ND No 
3 p.Leu243Gly NTAD 9 0.81 Affect protein 
function
low ND No 
4 p.Val406Gly CH1 6 0.54 Affect protein 
function
high ND Yes
5 p.Asp426Gly CH1 6 0.54 Tolerated high ND No 
6 p.Cys427Gly CH1 6 0.54 Affect protein 
function
high ND Yes
7 p.Asn435Lys CH1 6 0.54 Affect protein 
function
high ND Yes
8 p.Lys439Asn CH1 6 0.54 Affect protein 
function
low ND No 
9 p.His1235Gln CH2 8 0.72 Affect protein 
function
low No No 
10 p.Asp1340Ala CH2 10 0.9 Affect protein 
function
low No No 
11 p.Glu1384Gly CH2 10 0.9 Tolerated high Yes* Yes
12 p.Glu1459Asp CH2 10 0.9 Tolerated high Yes Yes
13 p.Ser1533Cys HAT 10 0.9 Affect protein 
function
high ND Yes
14 p.Val1613Met HAT 9 0.81 Affect protein 
function
low ND Yes
15 p.Leu1668His HAT 11 1 Affect protein 
function
low Yes Yes
16 p.Glu1724Lys CH3 11 1 Affect protein 
function
low Yes Yes
17 p.Thr1735Arg CH3 10 0.9 Tolerated high ND Yes
18 p.Gln1765His CH3 10 0.9 Affect protein 
function
low ND No
*not statistically signifi cant 
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searched the literature and databases to access established 
structures of the normal human CREBBP protein. A recent 
publication (Liu et al. 2008) describes the EP300 HAT 
domain using high-resolution X-ray crystal structure. 
CREBBP has a high homology with EP300 (88% in the HAT 
region – supplementary fi gure 2). Thereby, using the EP300 
HAT domain as a reference structure, we could analyse the 
effects of fi ve missense mutations identifi ed in our study 
located in the HAT region – p.Asp1340Ala, p.Leu1668His, 
p.Glu1384Gly, p.Ser1533Cys and p.Glu1459Asp. The 
analysis revealed that the fi rst two of these mutations were 
present in the helix region, p.Glu1384Gly and p.Ser1533Cys 
in the β-sheet region, while p.Glu1459Asp was located in 
the L1 loop. The latter region has been identifi ed as the 
substrate-binding loop of the CREBBP protein essential for 
HAT activity (Liu et al. 2008). By this derivation, only the 
p.Glu1459Asp associated mutation can be considered to have 
the maximum probability of being pathogenic (fi gure 4A). 
Similarly, we accessed a structure in the Protein Data 
Bank (1U2N) (http://www.rcsb.org/pdb/home) describing 
the CREBBP amino acid 340–442 regions that encompass a 
part of the NTAD (CH1) domain. Using this as a reference 
structure, we could analyse the effects of fi ve missense 
mutations identifi ed in our study which were located in 
this region and affected fi ve amino acids – p.Val406Gly, 
p.Asp426Gly, p.Cys427Gly, p.Lys439Asn and p.Asn435Lys. 
The former four were localized to a part of the loop region 
while p.Asn435Lys was localized to the helix region (fi gure 
4B). The exact implications of these mutations cannot be 
assessed since the signifi cance of these regions with respect to 
the functionality of the protein have not been identifi ed as yet. 
Analysing the 18 missense mutations on the basis of 
the three parameters outlined above, we thus predict that 
10 of these could be potentially pathogenic (table 1). It 
may be noted that certain mutations which were predicted 
to be tolerated through SIFT analysis are considered by
us as being pathogenic, since they have been earlier
reported to be critical for HAT activity (Bannister and 
Kouzarides 1996; Ogryzko et al. 1996; Giles et al. 1997; 
Kalkhoven et al. 2003).
3.4 Reduced CREBBP HAT activity in RSTS patient-de-
rived cells
An assessment of functionality serves as an essential 
validation of the predicted pathogenicity of missense 
mutations. We thus determined whether the missense 
mutations identifi ed in our study (fi gure 2A) disrupt the HAT 
activity of CREBBP in cells derived from RSTS patients.
To this end, we used EBV-transformed lymphoblastoid
cell lines established in our laboratory from patients 
GM3SF, RSTS3a, RSTS5a and RSTS6a. Equal amounts 
of nuclear extracts from patient cell lines were used in the 
acetylation assay and compared with those from cell lines 
derived from four healthy control individuals (fi gure 4C[i], 
4C[ii]). To further ascertain that the altered HAT activity 
Table 2. Distribution of missense mutations reported in the existing RSTS database based on their conservation index
No. Mutation Domain Conservation across 
species (number)#
Conservation index 
(CI)$
References 
1 p.Ala981Thr No Domain 6 0.54 Coupry et al. 2002
2 p.Tyr1175Cys HAT 10 0.9 Bartsch et al. 2002
3 p.Glu1278Lys HAT 10 0.9 Kalkhoven et al. 2003; 
Roelfsema et al. 2005
4 p.Glu1278Gly HAT 10 0.9 Udaka et al. 2005
5 p.Arg1378Pro CH2 7 0.6 Murata et al. 2001
6 p.His1413Pro CH2 11 1 Udaka et al. 2005
7 p.Asp1435Val CH2 11 1 Bartsch et al. 2005
8 p.Thr1447Ile CH2 11 1 Roelfsema et al. 2005
9 p.Tyr1450His CH2 11 1 Roelfsema et al. 2005 
10 p.His1470Arg CH2 11 1 Roelfsema et al. 2005 
11 p.Tyr1482Cys CH2 11 1 Bentivegna et al. 2006
12 p.Asp1651His HAT 11 1 Murata et al. 2001
13 p.Arg1664His HAT 11 1 Roelfsema et al. 2005
14 p.Asn1978Ser HAT 8 0.72 Bartsch et al. 2005
#Conservation was screened across 11 species including C. elegans, M. aegyptica, D. rerio, X. tropicalis, G. gallus, M. 
musculus, R. norvegicus, C. familiaris, F. catus, P. troglodytes.
$Conservation index was calculated by the following formula=Frequency of conservation*100/total number of species
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would be refl ected by changes in the CREBBP protein, we 
checked the expression levels of a similar HAT molecule, 
EP300. Thus, western blotting using nuclear extracts from 
the lymphoblastoid cell lines from these patients as well as 
control individuals revealed that both CREBBP as well as 
EP300 protein expression levels in all the controls as well 
as the patients – GM3SF, RSTS3a, RSTS5a and RSTS6a 
– were similar (fi gure 4C[iii]). Thereby, alterations in 
Figure 4. Depiction of amino acid residues in the HAT region (A) and CH1 region (B) of CREBBP mutated in our study. (A) Structure of 
the EP300 HAT region (adopted from Liu et al. 2008). (B) Structure of CH1 region of murine CREBBP. The letters ‘L’ and ‘H’ represent 
the loop and helix region of the protein. Actual amino acid residues in human CREBBP are represented in parentheses/missense mutations 
at the same amino acids identifi ed in the study. (C) (i) Comparable HAT activities of lymphoblastoid cell lysates from four healthy 
individuals used as control. (ii) Graphical representation of the protein estimation of the HAT reaction cocktail used for each assay. It may 
be noted that comparable protein levels were used for each assay. (iii) Western blotting showing expression levels of CREBBP and EP300 
in controls and RSTS patients. Numbers 1–4 are the controls used, numbers 5, 6, 7, 8 are RSTS patients RSTS6a, GM3SF, RSTS3a and 
RSTS5a, respectively. (iv) Reduced CREBBP acetyltransferase activity in cells derived from RSTS patients. Epstein–Barr virus (EBV)-
transformed lymphoblastoid cell lysate from healthy control and RSTS patients were used to acetylate histones in vitro. The data shown are 
representative of HAT assays done in triplicate and depicted as mean + SEM. *P<0.05, **P<0.01, ***P<0.001. The level of acetylation 
for the control lane was set to 100%. Patient RSTS5a showed ~87% less activity whereas GM3SF, RSTS3a, RSTS5a and RSTS6a showed 
~17%, 27% and 20% less activity as compared to the control individual. The mutations in italics are the common mutations found in the 
patients and those in bold are the mutations specifi c to the patient.
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HAT activity (if any) were likely to result from the specifi c 
CREBBP mutations observed in the corresponding patients.
As seen in fi gure 4C(iv), the overall acetyltransferase 
activity of RSTS-derived cell lines was identifi ed to 
be lower than those derived from healthy individuals; 
although a signifi cant reduction was associated with only 
two samples – RSTS3a and RSTS5a. RSTS3a is associated 
with the missense mutations p.His1235Glu, p.Asp1340Ala 
and p.Glu1459Asp, and any/all of these could be critical 
modulators of HAT activity. However, p.His1235Glu and 
p.Asp1340Ala were also present in patient GM3SF, wherein 
a signifi cant decrease in HAT activity was not identifi ed. 
From these observations, we deduce that the reduced HAT 
activity in RSTS3a may possibly be attributed to the missense 
mutation p.Glu1459Asp. Along similar lines, the reduction 
in HAT activity in patient RSTS5a may involve either/or two 
missense mutations p.Leu1668His and p.Glu1724Lys but 
not p.His1235Glu, which was present in GM3SF cells. The 
functional implications of missense mutations identifi ed in 
other patients could not be established, since lymphoblastoid 
cell lines were not established from these samples. 
In conclusion, at least 3 of the missense mutations 
identifi ed – p.Glu1459Asp, p.Leu1668His and p.Glu1724Lys 
– show a signifi cant infl uence on the HAT function of 
CREBBP. 
3.5 Phylogenetic similarity of the missense mutations
Phylogenetic analysis reveals that individuals with different 
nucleotide variation(s) form separate branches on the 
phylogenetic tree. The further a branch is from the wild 
type, the more the number of sequence variations that 
can be expected. Hence, branch length is considered as 
an additional parameter of divergence (fi gure 5). We thus 
analysed the RSTS patients in our study to assess their 
phylogenetic proximity. Patients RSTS10a and RSTS13a 
showed exclusive mutations and hence formed separate 
branches. The pairs RSTS8a and RSTS9a, GM1LBL and 
RSTS6a, RSTS11a and RSTS12a occupy the same branch 
since the members within each pair share some common 
nucleotide changes. GM3SF, RSTS3a, RSTS4a, RST5a and 
RSTS7a lie on one branch as these samples showed some 
common nucleotide variations; divergence emerging due to 
individual mutations is indicated through the sub-branches 
that arise subsequently. Based on the length of its sub-
branch, RSTS5a especially may be deduced to be drastically 
deviant from the wild type, a fact that is in conformation 
with the identifi cation of a maximum number of nucleotide 
changes in the CREBBP gene in this patient (supplementary 
tables 4 and 5). 
3.6 Analysis of SNPs in CREBBP in the Indian
population
Amplifi cation and sequencing of the exon, intron and 
I/E boundary regions of the CREBBP gene in 100 control 
individuals to ascertain polymorphisms in the Indian 
population led to the identifi cation of a total of 33 SNPs 
(supplementary table 8). Of these, seven SNPs were located 
in the exon regions, two in the intron and 24 in the I/E 
Figure 5. Phylogenetic tree showing distribution coexistence of the Indian RSTS patients in the study.
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boundaries. The distribution of these SNPs in the population 
was as follows: 24 SNPs were identifi ed exclusively in the 
controls; fi ve in controls, RSTS patients and parents; one 
in controls and RSTS patients; and three in controls and 
parents. Among the former, the p.Ile1300Ile polymorphism 
has been reported earlier (rs129974-dbSNP), while the 
rest are novel. Four of the intron SNPs – c.3836+77T>C 
(rs129982), c.3836-173T>C (rs129981), c.2158+81T>C 
(rs130002), c.4394+42G>A (rs129667) – have been 
reported. Although at present the 28 novel SNPs may be 
considered to be specifi c to the Indian population, their 
presence is not reported in the 1000 genome database that 
includes a large number of Gujarati individuals among many 
individuals from other populations. This warrants further 
investigations. 
3.7 Allelic association of the nucleotide changes between 
cases and controls and linkage disequilibrium studies
The exact molecular–genetic aetiology of RSTS is still 
not clearly understood; most groups report the de novo 
occurrence of these mutations. A rare case study has been 
reported in a family wherein the mother expressed partial 
symptoms, while the child expressed most RSTS symptoms 
along with more pronounced clinical features (Petrij et al. 
2000a). Such fi ndings are suggestive of co-segregation of 
genetic markers. Further, one cannot rule out the possibility 
of somatic mosaicism, which has been documented in 
conditions such as tuberous sclerosis (Verhoef et al. 1999), 
wherein the parents may be unaffected but the offspring 
may be affected. Earlier reports have also speculated on 
its occurrence in RSTS but the frequency of somatic and 
germ-line mosaicism in the RSTS families described were 
found to be low (Hennekam et al. 1990; Stevens et al. 1990; 
Chiang et al. 2009). With this rationale, we applied linkage 
disequilibrium analyses in our study, which would give an 
insight of co-segregation or association between a genetic 
marker (variant) identifi ed in the CREBBP gene in our study 
and RSTS. 
Initial haplotype analysis (haplotype frequency estimation 
and pair-wise linkage disequilibrium between the SNPs and 
mutations) using Gevalt was followed with single locus and 
multi-marker haplotype association tests and chi-square and 
P value (uncorrected) estimations for the allele frequency 
computation in RSTS cases vs controls (supplementary 
table 9). Ten thousand permutations for association results 
of individual markers within our study were carried out 
towards obtaining a measure of signifi cance corrected for 
multiple testing biases. A P value of <0.05 was considered 
statistically signifi cant. The entire gene was defi ned as a 
single haplotype block of 120 kb within which markers 
with D’ values ≤1 were identifi ed. Of these, only markers 
with D’ values = 1 were selected as such a state is indicative 
of signifi cantly high linkage disequilibrium in which the 
likelihood of marker separation is low during recombination 
events. 
Eight groups of markers were thus identifi ed 
(supplementary table 3). These groups were further screened 
to identify two subgroups in which an association existed 
between the identifi ed mutation and SNPs. The fi rst of 
these two groups had nine markers including one known 
SNP (rs129974), and eight novel variants specifi c to the 
Indian population including one missense mutation (table 
3). Marker M32 was dropped during further analysis as a χ2 
analysis revealed its association with the other markers in the 
group to be statistically insignifi cant (P=0.1874). Markers 
M19, M28, M31, M60, M61 are located in the intron regions 
or I/E boundaries and hence may either be silent or have 
no obvious effect on biological function. Interestingly, the 
remaining markers M26, M33, and M41 suggested to be 
Table 3. First group of markers identifi ed in signifi cant association with RSTS in Indian patients using linkage disequilibrium 
analysis
No. Markers Alleles Exact position dbSNP/Novel Samples
1 M19 A/G IVS27+238A>G Novel GM1LBL
2 M26 T/G p.Asp1340Ala Novel GM3SF, RSTS3a
3 M28 T/G IVS23-277T>G Novel GM1LBL
4 M31 C/G IVS23+103C>G Novel GM1LBL
5 M32 G/T IVS23+93G>T  rs129974 * C21, C17, GM1LBL
6 M33 C/T p.Ile1300Ile rs3025684 C1, C23, GM1LBL, GM3SF, RSTS3a, RSTS3c, RSTS4a,  
RSTS4b, RSTS6a, RSTS6b
7 M41 G/C IVS21-206G>C Novel C8, GM3SF, RSTS3a, RSTS3b, RSTS4a, RSTS4b, 
RSTS4c, RSTS5a, RSTS5c, RSTS6c, RSTS7a
8 M60 C/T IVS8-235C>T Novel RSTS3a
9 M61 A/G IVS8-237A>G Novel RSTS3a
*Association not signifi cant 
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in complete linkage disequilibrium (D’=1), were identifi ed 
in association within the family of the patient RSTS3a. In 
this case, all the three markers were present in the patient 
whereas the father possessed M33 and M41 (SNPs rs129974 
and c.3836-206G>C), but lacked M26 (missense mutation 
p.Asp1340Ala). This suggests the de novo emergence of the 
mutation, though associated with the two SNP markers that 
were inherited from the father. This is further strengthened 
by the r2 values of these markers, which were found to be <1, 
indicating a possibility of recombination at these regions. 
Similarly, all the three markers also coexisted in GM3SF; 
unfortunately, due to a lack of samples from the parents, a 
similar pattern of marker inheritance could not be mapped. 
Based on the signifi cant P values of the three markers M26, 
M33 and M41 in addition to the analyses, we conclude that 
they may be highly associated with RSTS; however, the 
possibility of some recombination events cannot be totally 
ruled out.
The second group (table 4) included 11 markers of 
which M48 is a known SNP (rs130002). Six markers 
within this group – M30, M46, M49, M67, M68 and M69 
– were identifi ed in the intron or I/E boundary regions and 
may be silent. Further analysis revealed that markers M48 
(rs130002) and M55 (missense mutation, p.Asn435Lys) 
were in complete linkage disequilibrium, i.e. they expressed 
D’=1, yet the possibility of some recombination around these 
regions was indicated, as values for r2 were <1. These two 
markers were identifi ed in patients RSTS11a and RSTS12a; 
unfortunately, due to a lack of samples from their parents, 
marker inheritance could not be mapped. The remaining 
marker pairs M64 and M67, M65 and M67, and M66 and 
M67, in addition to having D’=1, also depicted r2 = 1, 
suggesting that they were inseparable during recombination 
events and inheritance. All these three marker pairs were 
present in RSTS13a; however, inheritance could not be 
identifi ed due to unavailability of parent samples. 
4. Discussion
The present study is a fi rst report on the molecular 
investigations of the CREBBP gene in RSTS patients in the 
Indian population, together with SNP profi ling of 100 control 
individuals. All thirteen RSTS patients exhibited nucleotide 
changes in the CREBBP gene. Ten of the 13 patients had 
exon as well as intron mutations, whereas three patients 
(RSTS7a, RSTS8a, and RSTS9a) showed exclusive intron 
mutations. Previous reports on RSTS patients (Bartsch et al. 
2005; Roelfsema et al. 2005) suggest an even distribution 
of mutations in CREBBP; mutations identifi ed in our study 
were primarily localized in the CH1, CH2, CH3 and HAT 
domains. Unlike previous reports, we did not identify 
any truncating mutations that could lead to a premature 
formation of a stop codon and protein truncation (Petrij et al. 
2000a,b; Bartsch et al. 2002; Coupry et al. 2002; Bentivegna 
et al. 2006). Sixteen of the nucleotide changes arose de novo 
(fi gure 1; supplementary tables 3 and 4); 29 others could 
not be ascertained due to lack of corresponding data from 
parent samples. Fourteen variants identifi ed in this study 
in the patients and parents, and four in the parents alone, 
were classifi ed as mutations. However, one cannot rule out 
the possibility of these being polymorphisms specifi c to the 
particular ethnic subgroup of the patients. 
All the 18 missense mutations identifi ed in our study 
were subjected to pathogenicity assessment based on their 
CI, SIFT analysis and structural modifi cations in the protein 
structure due to these mutations. The application of these 
analyses led to the identifi cation of 10 novel pathogenic 
mutations. Since it has been earlier reported that inactivation 
of HAT function is suffi cient to cause RSTS (Kalkhoven et 
al. 2003), through functional assays we identifi ed that three 
mutations located in the HAT domain – p.Glu1459Asp, 
p.Leu1668His and p.Glu1724Lys – brought about signifi cant 
reduction in acetyltransferase activity. This, therefore, 
Table 4. Second group of markers identifi ed in signifi cant association with RSTS in Indian patients
No. Markers Alleles Exact position dbSNP/Novel Samples
1 M30 C/A IVS23+164C>A Novel RSTS12a
2 M46 T/C IVS18+3T>C Novel RSTS12a
3 M48 T/C IVS11+81T>C rs130002 C2,C17,C63, RSTS4a, RSTS12a
4 M49 C/A IVS10+26C>A Novel RSTS12a
5 M55 A/C p.Asn435Lys¥ Novel RSTS11a,RSTS12a
6 M64 T/A p.Ser1533Cys¥ Novel RSTS13a
7 M65 T/G p.Val89Gly¥ Novel RSTS13a
8 M66 A/C p.Asp35Ala¥ Novel RSTS13a
9 M67 G/C IVS21-28G>C Novel RSTS13a
10 M68 C/A IVS30-178C>A Novel RSTS13a
11 M69 C/A IVS30-178C>A Novel RSTS13a
¥Missense mutations
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clearly underscores the in vivo relevance of these amino 
acids in CREBBP HAT function. The consequence of four 
other missense mutations – p.Ser1533Cys, p.Val1613Met, 
p.Thr1735Arg and p.Gln1765His – identifi ed in the other 
patients could not be determined. However, we suggest that 
these could lead to a reduced HAT activity due to (i) a high 
CI (table 1), and (ii) their location in a region previously 
identifi ed to be a critical determinant of HAT functionality 
(aa 1098–1757 in human CREBBP corresponding to mouse 
region aa 1099–1758) (Bannister and Kouzarides 1996; 
Ogryzko et al. 1996; Giles et al. 1997; Kalkhoven et al. 
2003). (iii) Ser1533 is a part of the conserved coenzyme A 
(CoA) binding site (Kalkhoven et al. 2003) and mutations 
would possibly affect HAT activity and could be putative 
pathogenic mutations. We cannot negate the signifi cance 
of the missense mutations identifi ed outside the HAT 
domain, which might, for example, disrupt HAT–substrate 
interactions or destabilize the CREBBP protein, giving rise 
to the same phenotype as RSTS. 
The effects of silent mutations were diffi cult to predict 
since they were always present along with missense 
mutations, except in patient GM1LBL, who lacked missense 
mutations. However, such mutations may be pathogenic as 
reported earlier in Marfan syndrome and ataxia telangiectasia 
(Liu et al. 1997; Teraoka et al. 1999) or may complement the 
effects of missense mutations in the patients. Similarly, it is 
diffi cult to assess the exact implication of intron mutations 
in causing the disease; however, silent mutations and 
intron variants may directly/indirectly affect the specifi c 
regulatory events involving CREBBP. Phylogenetic analysis 
indicated that while the nucleotide changes in CREBBP are 
highly diverse in RSTS, a high CI of the specifi c amino 
acid residues implicated in missense mutations highlights 
the importance of these mutated specifi c residues in the 
normal functioning of the protein and thus may possibly be 
bona fi de causative lesions leading to manifestation of the 
syndrome. Identifi cation of several novel polymorphisms 
that may be specifi c to the Indian population is an important 
feature of this study.
Linkage disequilibrium analysis revealed the following 
associations: (i) p.Asp1340Ala (missense mutation) with 
rs129974 and c.3836-206G>C (a novel SNP), and (ii) 
p.Asn435Lys (missense mutation) with rs130002 and 
(iii) SNPs rs129974, rs130002 and a novel SNP (c.3836-
206G>C). Similar associations have been reported in other 
genetic conditions including Wolfram syndrome (Sandhu 
et al. 2007), schizophrenia (Chowdari et al. 2002) and 
systemic lupus erythematous (Graham et al. 2006). Thus, 
one may predict polymorphisms as one of the risk factors 
in the pathogenesis of RSTS; however; a larger sample size 
may be required to further validate this fi nding.
CREBBP is a protein for which a plethora of functions 
have been identifi ed, including chromatin remodelling, 
as a co-activator for several transcription factors through 
its capacity to provide a scaffold for binding of several 
proteins, or providing a bridge for proteins in DNA binding 
(Ogryzko et al. 1996). Mutations in the conserved CH 
domains of CREBBP could lead to functional aberrations 
not only in basal transactivation, but also in the cascade of 
events that follow protein–protein interactions. The CH1 
domain is also implicated in the activation of appropriate 
transcription of genes during development of the skeletal 
framework (Tsuda et al. 2003). During haematopoiesis, 
myogenesis and chondrocyte differentiation, binding of the 
CH3 domain of CREBBP to the transcription factors GATA-
1, MyoD and Sox9 are required for lineage differentiation 
(Polesskaya et al. 2000; Blobel 2002; Tsuda et al. 2003). 
Thereby, mutations in CH3 could be involved in aberrant 
haematopoiesis and myogenesis, while mutations in the 
CH1 and/or CH3 domains could contribute to the skeletal 
abnormalities observed in RSTS patients. 
The HAT domain, besides mediating acetyltransferase 
activity, is also known to interact with other transcription 
factors including Twist, GLI3 (Dai et al. 1999) or have a 
high degree of homology in structure and functions with 
CREBBP, e.g. EP300 with a 63% homology (Udaka et 
al. 2005). Mutations in such genes may also contribute to 
RSTS; altered Twist signalling is reported to complement 
the symptomatology of RSTS (Goodman and Smolik 2000). 
Overlapping phenotypes in individuals in whom partial 
symptoms of RSTS may be observed also correlate with other 
genes that have a high degree of homology with CREBBP/ 
similar HAT function, e.g. EP300 mutations have recently 
been reported to play a minor role in the aetiology of RSTS 
(Roelfsema et al. 2005), but could lead to phenotypes other 
than classical RSTS (Zimmermann et al. 2007). Thus, one 
cannot rule out the possibility of involvement of mutations in 
other genes besides CREBBP in the manifestations of RSTS. 
This is further highlighted as a large number of patients do 
not harbour mutations in the implicated genes – CREBBP/
EP300 (Bentivegna et al. 2006). Another possibility is 
that epigenetic regulation of chromatin packaging and 
accessibility to specifi c transcription factors may be altered/
disrupted during development; the fi nding that treatment 
with histone deacetylase (HDAC) inhibitors can alleviate 
some of the symptoms of RSTS patients supports this notion 
(Hallam and Bourtchouladze 2006).
In conclusion, the present study demonstrated a high 
detection rate (10 out of 13 patients. [76.9%] showed the 
presence of causative mutations) in typical Indian RSTS 
patients. Further, 10 novel missense mutations that may 
be pathogenic were identifi ed in the CREBBP gene in 
RSTS patients. The association of SNPs revealed in this 
study with RSTS suggests their additional contribution to 
the pathogenesis of the syndrome, which can be studied 
further in patient–parent cohorts. Together, our fi ndings may 
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enhance the understanding of this syndrome at the molecular 
level.
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Supplementary table 2. Primers used for CREBBP gene amplifi cation
Primer Exons Forward Reverse
CBPE2 Exon2 5′-CTG TTT TCG CGA GCA GGT-3′ 5′-ATC GGT ATC CGC GAC CAC-3′
CBPE3a Exon3 5′-AACGTGGCAGTTGGAGAGC-3′ 5′-GTGCTGGCTGCCTGTTTAG-3′
CBPE3b Exon3 5′-TAAACAGGCAGCCAGCACC-3′ 5′-TACCTTGGCCATGCCTCCTG-3′
CBPE4 Exon4 5′-TCACCACAGCTGATGTTACCTC-3′ 5′-TCCTGTTGCTAGCTCATCACAG-3′
CBPE5 Exon5 5′-GTGGTCGGTATTATCCATCAGC-3′ 5′-GGCAAATTCTTCCTGACCTC-3′
CBPE6 Exon6 5′-TGTTTGTAAGTTGAGGACTGCC-3′ 5′-TGTACCTTGGGCTGCTGTC-3′
CBPE7 Exon7 5′-TTCCTTTCTCCCTAGGCTTG-3′ 5′-GAGAGTTCCTTCACCTACCCAG-3′
CBPE8 Exon8 5′-GGTGGCATGTTGTTATCGTC 5′-AAGTCAGGAGAGCCAAGTGATG-3′
CBPE9 Exon9 5′-GTGGTGGCAGAAGAACCTTAC-3′ 5′-AGAGTGTGGGAATCTCTGGC-3′
CBPE10 Exon10 5′-AGGTGATTCTCCCGCCTCAG-3′ 5′-ATCTGGGAAGTCTCCTTGGTC-3′
CBPE11 Exon11 5′-GCCAGTGTACTCAATGAGGAAG-3′ 5′-ACATCAACAGCTTCTGCAGG-3′
CBPE12 Exon12 5′-CTC TCT TGG GAA GGC CCT TTA C-3′ 5′-GAG GCA GGA GAA TGG TGT GAA C-3′
CBPE13 Exon13 5′-TGTCCTCGTCCTTCCCTGGTAC  -3′ 5′-TGTGAGAGGGAGGGCTATCTGC -3′
CBPE14 Exon14 5′-TGTGCTTGCCATCCTCTGGG -3′ 5′-TCATGGGTCCTTCTCACTCGC   -3′         
CBPE15 Exon15 5′-CTC TGT CCA TTT CTG GTA GGG  -3′ 5′-GGA TGG TCT TGA ACT CAT GGG  -3′
CBPE16 Exon16 5′-TCTGGCTGCTGTTACCTCCCTC-3′ 5′-TACCCATGGCAGGCTCCAAG -3′
CBPE17 Exon17 5′-CTG ACT CTG TGC TGA AGC GAC-3′ 5′-CTC TCA CTC CTG CCA TGA GC-3′
CBPE18 Exon18 5′-CCACCATGCCCAGCCTGAAAT G-3′ 5′-TCCAAGGACCAGGGCTTCATG-3′
CBPE19 Exon19 5′-CCCAGCCGATTCTATGTAGCAG -3′ 5′-CTCCCAGTATACAGGCGTGGTC -3′
CBPE20 Exon20 5′-CTGAAGCGATGTGATGGGTG-3′ 5′-TGTCGCCAAGGCTGATAAC-3′
CBPE21 Exon21 5′-GATGATGGCCTGTGATGTGTGC -3′ 5′-TGGTCAAGGCTGCAGTGAGTC -3′
CBPE22 Exon22 5′-GGCGTGGTGGTTTGTACCTG -3′ 5′-CCCACAACCCACTCCATAAGG-3′
CBPE23-24 Exon23&24 5′-CCCAGAGAACAAGGTGTGGAC G-3′ 5′-TTGACAACCGAACCTCAGAACC -3′
CBPE25 Exon25 5′-ATCCATCTGCTCCGCCCTAGAG-3′ 5′-GCTACTGCACGCATTCGCTG -3′
CBPE26 Exon26 5′-CATTCACAGAGGTGCAGTTCCC -3′ 5′-TAGGTAAGAGCGGGTCCCACAC-3′
CBPE27 Exon27 5′-GAGCCCATGAGGTTGAGGTTGC -3′ 5′-TTCAGGTGATCCACCGCAGCAG -3′
CBPE28 Exon28 5′-CCCAAGGGAGAAGTGTTGCAG -3′ 5′-TGCCCACTGATGGAAACAGC-3′
CBPE29 Exon29 5′-CTGTTTCCATCAGTGGGCATTG -3′ 5′-TTTACATCAGCGGGTTGTGTCC -3′
CBPE30 Exon30 5′-TGGAATCTTCCGCATCTGGTTG -3′ 5′-CCTGATGCCTTGGGATGGAAC-3′
CBPE31 Exon31 5′-ATCAGGGCCATCAGGCTCAG-3′ 5′-GCGGGTGTTTCCAGCCATTTAG-3′
CBPE32 Exon32(i) 5′-GCTGTTGCCAGGAGTGAAGGTC-3′ 5′-GCTGGCGGAGCTTGTGTTTG-3′
CBPE32 Exon32(ii) 5′-TCATCGCCCTCTGCTGCTAC -3′ 5′-TGGGCCTGCATGGATATCAC-3′
CBPE32 Exon32(iii) 5′-CCTGTACCGGGTGAACATCAAC -3′ 5′-GCTGCCTCCGTAACATTTCTCG -3′
CBPE32 Exon32(iv) 5′-CATGAACCCAGGACACAACCC -3′ 5′-GGGAGCATTGCACTCTGTTCG -3′
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Supplementary table 3. List of eight groups classifi ed on the basis of markers showing independent association or interdependency
First group      
S. No. Markers Alleles Exact position Samples dbSNP/Novel
1 M2 C/A 3185 RSTS10a Novel
2 M6 A/T 4503 RSTS10a Novel
3 M10 C/T 5478 RSTS10a Novel
Second group      
1 M7 C/T 4628 RSTS5a Novel
2 M8 T/A 4794 RSTS5a Novel
3 M53 T/C 65411 RSTS5a Novel
4 M54 C/G 65427 RSTS5a Novel
5 M56 A/C 65465 RSTS5a Novel
6 M57 T/C 65467 RSTS5a,RSTS11a Novel
7 M58 A/C 65527 RSTS5a Novel
8 M59 T/G 65648 RSTS5a Novel
9 M62 A/T 123800 RSTS11a Novel
10 M65 T/G 124424 RSTS13a Novel
11 M66 A/C 124262 RSTS13a Novel
Third group      
1 M12 G/T 5540 C75,C76,C86 Novel
2 M29 T/G 18478 C75,C83 Novel
3 M52 C/T 65348 C86 Novel
Fourth group      
1 M13 C/T 9919 C2,C13,C17 Novel
2 M36 T/C 25081 C1,C2,C3,C6,C9,C13,C17,C19,C67,C69,RSTS6b Novel
3 M38 G/A 25230 C20,C69 Novel
Fifth group      
      
1 M14 A/T 10029 C5 Novel
2 M15 A/C 10054 C5,C9,C16 Novel
3 M16 T/G 10107 C9 Novel
4 M17 T/C 10152 C5,C9 Novel
Sixth group      
1 M19 A/G 11755 GM1LBL Novel
2 M26 T/G 13946 GM3SF,RSTS3a Novel
3 M31 T/G 18607 GM1LBL Novel
4 M32 C/G 18617 C21,C17,GM1LBL Novel
5 M33 G/T 18724 C1,C23,GM1LBL,GM3SF,RSTS3a,RSTS3c,RSTS4a
,RSTS4b,RSTS6a,RSTS6b
 rs129974 
6 M61 C/T 98804 RSTS3a Novel
7 M41 G/C 25445 C8,GM3SF,RSTS3a,RSTS3b,RSTS4b,RSTS4a,RSTS
4c,RSTS5a,RSTS5c,RSTS6c,RSTS7a
Novel
8 M60 C/T 98802 RSTS3a Novel
9 M28 A/G 18455 GM1LBL Novel
Seventh group      
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1 M30 C/A 18547 RSTS12a Novel
2 M69 A/T 23282 RSTS13a Novel
3 M46 T/C 32284 RSTS12a Novel
4 M48 T/C 51363 C2,C17,C63,RSTS4a,RSTS12a rs130002
5 M49 C/A 52107 RSTS12a Novel
6 M55 A/C 65439 RSTS11a,RSTS12a Novel
7 M65 T/G 124424 RSTS13a Novel
8 M66 A/C 124262 RSTS13a Novel
9 M64 T/A 9600 RSTS13a Novel
10 M67 G/C 3334 RSTS13a Novel
11 M68 C/A 5533 RSTS13a Novel
Eighth group      
1 M43 G/A 30603 C2,C19,C52,C69 Novel
2 M44 A/T 31015 C18 Novel
3 M45 A/C 31609 C62 Novel
4 M50 C/T 54071 C62 Novel
Supplementary table 4. Exon mutations in RSTS patients in the Indian population
S.No Gene Position Sense / 
Missense
Patient Exon Amino acid 
change
Novel/de novo/SNP Domain
1 g.3276G>C missense RSTS13a 32 p.Thr1735Arg Novel CH3
2 g.4503A>T missense RSTS10a 31 p.Gln1765His De novo; novel CH3
3 g.4627C>T missense RSTS5a 31 p.Glu1724Lys De novo; novel CH3
4 g.4794T>A missense RSTS5a 31 p.Leu1668His De novo; novel HAT
5 g.9600T>A missense RSTS13a 29 p.Ser1533Cys Novel HAT
6 g.5262C>T missense RSTS13a 30 p.Val1613Met Novel HAT
7 g.12009C>T missense RSTS3a 27 p.Glu1459Asp Novel CH2
8 g.13140T>C missense RSTS6a 26 p.Glu1384Gly De novo; novel CH2
9 g.13946T>G missense GM3SF, RSTS3a 25 p.Asp1340Ala Novel CH2
10 g.25233A>T missense GM3SF, RSTS3a, 
RSTS4a, RSTS5a
21 p.His1235Gln Novel CH2
11 g.65427C>G missense RSTS5a 6 p.Lys439Asn De novo; novel CH1
12 g.65439A>C missense RSTS11a, RSTS12a 6 p.Asn435Lys Novel CH1
13 g.65465A>C missense RSTS5a 6 p.Cys427Gly De novo; novel CH1
14 g.65467T>C missense RSTS5a,  RSTS11a 6 p.Asp426Gly Novel CH1
15 g.65527A>C missense RSTS5a 6 p.Val406Gly De novo; novel CH1
16 g.123800A>T missense RSTS11a 3 p.Leu243Gly Novel NTAD
17 g.124262A>C missense RSTS13a 3 p.Val89Gly Novel NHRD
18 g.124424T>G missense RSTS13a 3 p.Asp35Ala Novel NHRD
19 g.4808C>T sense(silent) RSTS5a 31 p.Gly1663Gly De novo; novel HAT
20 g.5284C>T sense(silent) RSTS10a 31 p.Lys1605Lys De novo; novel HAT
21 g.5341C>T sense(silent) RSTS12a 30 p.Lys1586Lys Novel HAT
22 g.13894A>G sense(silent) GM3SF, RSTS3a 25 p.Val1357Val Novel CH2
23 g.13929A>G sense(silent) GM3SF, RSTS3a 25 p.Leu1346Leu Novel CH2
24 g.54717T>G sense(silent) GM3SF 8 p.Pro532Pro Novel KIX
25 g.65472T>C sense(silent) RSTS5a 6 p.Arg424Arg De novo; novel CH1
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Supplementary table 5. Intron mutations in  RSTS patients in the Indian population
S.No Gene position Exact position Patient Splice site Novel/De novo/SNP Domain
1 g.3334G>C c.3379-28G>C RST13a No Novel HAT
2 g.3185C>A c.3379+76C>A RSTS10a No Novel HAT
3 g.5478C>T c.4728-108C>T RSTS10a No De novo; novel HAT
4 g.5533C>A c.4890-178C>A RSTS13a No Novel HAT
5 g.11755A>G c.4394+238A>G GM1LBL No Novel HAT
6 g.12857A>G c.4113-154A>G RSTS6a No De novo; novel HAT
7 g..12833G>A c.4113-178G>A RSTS6a No De novo; novel HAT
8 g.14259G>A c.3982-277G>A RSTS4a No De novo; novel HAT
9 g.18455A>G c.3914-277A>A GM1LBL No Novel HAT
10 g.18547C>A c.3914+164C>A RSTS12a No Novel HAT
11 g.18617C>G c.3914+93C>G GM1LBL No Novel HAT
12 g.18607T>G c.3914+103T>G GM1LBL No Novel HAT
13 g.23282A>T c.3836-67A>T RST13a No Novel HAT
14 g.32284T>C c.3369+3T>C RSTS12a No Novel BROMO
15 g.51363T>C c.2113+81T>C RSTS4a No rs130002 KIX
16 g.52107C>A c.1941+26C>A RSTS12a No Novel KIX
17 g.54546C>T c.1676-235C>T RSTS3a No Novel KIX
18 g.54548C>T c.1676-237C>T RSTS3a No Novel KIX
19 g.65411T>C c.1330+3T>C RSTS5a Part of donor splice site De novo; novel KIX
20 g.65648T>G c.1216-121T>G RSTS5a No De novo; novel KIX
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Supplementary table 6. List of fi fteen nucleotide changes both in the patients as well as parents
S.No. Position Intron/Exon Samples Exact position/
change
dbSNP/Novel
1 g.25233A>G Ex21 RSTS3c,RSTS5a p.His1235HiS Novel
2 g.23474C>T IVS21 RSTS8a,GM1LBL,RSTS4b,RSTS6a,RSTS6b,RSTS8b c.3779-358C>T Novel
3 g.23289T>C IVS21 GM3SF,RSTS3a,RSTS3c,RSTS3b,RSTS4a,RSTS5a,RS
TS5b,RSTS6a,RSTS6c
c.3779-173T>C Novel
4 g.25445G>C IVS21 GM3SF,RSTS3a,RSTS3b,RSTS4a,RSTS4b,RSTS4c,RS
TS5a,RSTS5c,RSTS6c,RSTS7a
c.3779-206G>C Novel
5 g.10446C>A IVS27 RSTS3a,RSTS3b,RSTS3c,RSTS4c,RSTS5a,RSTS5b,R
STS6a,RSTS6b
c.4394-198C>A Novel
6 g.46880A>T IVS14 RSTS3b,RSTS4c,RSTS5b,RSTS6b,RSTS6c,RSTS8a,R
STS9a,RSTS9b,
c.2463+304A>T Novel
7 g.46900A>T IVS14 RSTS3b,RSTS4c,RSTS5b,RSTS6b,RSTS6c,RSTS8a,R
STS9a,RSTS9b
c.2463-284A>T Novel
8 g.46908A>C IVS14 RSTS3b,RSTS4c,RSTS5b,RSTS6b,RSTS6c,RSTS8a,R
STS9a,RSTS9b
c.2463+176A>C Novel
9 g.46966A>C IVS14 RSTS3b,RSTS4c,RSTS5b,RSTS6b,RSTS6c,RSTS8a,R
STS9a,RSTS9b
c.2463+218A>C Novel
10 g.47122_
47133insA
IVS14 RSTS3c,RSTS5a,RSTS5c,RSTS6a,RSTS9c c.24634+62insA Novel
11 g.12969G>A IVS25 RSTS6a,RSTS6b,GM1LBL,RSTS4b c.4113-42G>A Novel
12 g.13739T>C IVS25 RSTS3c,RSTS4a,RSTS4b c.4280+93T>C Novel
13 g.18795G>A IVS23 GM1LBL,GM3SF,RSTS3a,RSTS3c,RSTS4a,RSTS4b,
RSTS6b
c.3982+9G>A Novel
14 g.13190A>G IVS26 RSTS6a,RSTS6b c.4394+43A>G Novel
15 g.52289T>C IVS9 RSTS10b,RSTS10c,RSTS13a c.1941-139T>C Novel
Supplementary table 7. List of variants identifi ed in  the parents only
S.No. Position Intron/Exon Samples Exact position dbSNP/Novel
1 g.23322A>T IVS21 RSTS3c c.3836-206A>T Novel
2 g.23339A>C IVS21 RSTS3c c.3836-223A>C Novel
3 g.12796C>T IVS25 RSTS6b c.4280-215C>T Novel
4 g.25045A>C IVS21 RSTS6c c.3836+114A>C Novel
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Supplementary table 8. Single-nucleotide polymorphisms (SNPs) identifi ed in the Indian population SNPs located in exons
S. No. SNP Synonymous/ 
Non- 
synonymous 
Location Amino acid 
change
Known SNP 
(dbSNP)
Samples
1 g.25230G>A  Synonmous Exon21 p.Phe1236Phe Novel C20,C69
2 g.10107T>G  Synonmous Exon28 p.Ala1512Ala Novel C9
3 g.10152T>C  Synonmous Exon28 p.Lys1497Lys Novel C5, C9
4 g.18724G>T  Synonmous Exon23 p.Ile1300Ile  rs129974 C1, C23, 
GM1LBL, GM3SF, 
RSTS3a, RSTS3c, 
RSTS4a,RSTS6a
5 g.3227G>T  Non-synonmous Exon32 p.Asp1751Glu Novel C81
6 g.54203A>G  Synonmous Exon9 p.His595His Novel C57
7 g.123970T>C  Synonmous Exon3 p.Pro186Pro Novel C51
SNPs located in introns and I/E boundaries
S. No. SNP Intron Exact position Part of splice site Known SNP 
(dbSNP)
Samples
1 g.65348C>T Intron6 c.1330-3C>T No Novel C86
2 g.54071C>T Intron9 c.1823+94C>T No Novel C62
3 g.51363T>C Intron11 c.2113+81T>C No rs130002 C2, C17, C63, RSTS12a
4 g.31609A>C Intron18 c.3369-128A>C No Novel C62
5 g.31015A>T Intron20 c.3698-295A>T No Novel C18
6 g.30603G>A Intron20 c.3698+58G>A No Novel C2, C19, C52, C69
7 g.25469G>T Intron20 c.3698-230G>T No Novel C17
8 g.25445G>C Intron20 c.3698-206G>C No Novel C8, GM3SF, RSTS3a, 
RSTS3b, RSTS4b, 
RSTS4a, RSTS4c, 
RSTS5a, RSTS5c, 
RSTS6c,RSTS7a
9 g.25355T>G Intron20 c.3698-116T>G No Novel C19
10 g.25081T>C Intron21 c.3779+77T>C No rs129982 C1, C2,C3, C6, C9, 
C13, C17, C19, C67, 
C69, CRSTS6b
11 g.24982G>T Intron21 c.3779+177G>T No Novel C4, C6, C10, C22, 
RSTS3c, RSTS5b, 
RSTS5c, RSTS6b, 
RSTS6c
12 g.23289T>C Intron21 c.3779-173T>C No rs129981 C1, C8, C21, 
C24,GM3SF, RSTS3a, 
RSTS3c, RSTS4a, 
RSTS5a, RSTS5b, 
RSTS6a, RSTS6c
13 g.18617C>G Intron23 c.3914+93C>G No Novel C21, C17, GM1LBL
14 g.18478T>G Intron23 c.3914+232T>G No Novel C75, C83
15 g.13013C>A Intron25 c.4113-3C>A No Novel C53
16 g.12969G>A Intron26 c.4280+42G>A No rs129667 C56,RSTS6a,RSTS6b,
GM1LBL,RSTS4b
17 g.11973T>A Intron27 c.4394+19T>A No Novel C10
18 g.9919C>T Intron28 c.4560+264C>T No Novel C2, C13, C17
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19 g.10029A>T Intron28 c.4560+54A>T No Novel C5
20 g.10054A>C Intron28 c.4560+19A>C No Novel C5, C9, C16
21 g.10268A>T Intron28 c.4560-20A>T Part of acceptor 
splice site*
Novel C13,16
22 g.5540G>T Intron30 c.4890-170G>T No Novel C75, C76, C86
23 g.5522A>G Intron30 c.4890-152A>G No Novel C75, C76, C43, 
RSTS10b, C43
24 g.5148C>A Intron31 c.5172+61C>A No Novel C76
25 g.3425A>T Intron31 c.5172-119A>T No Novel C77, C78, C81, C82, 
C83, C85
26 g.3372C>T Intron31 c.5172-65C>T No Novel C75
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Supplementary table 9. Calculated chi-square and P values 
(uncorrected) for the allele frequencies in RSTS cases vs 
controls
S.No. Name Chi-square values Uncorrected P value
1 M1 0.116 0.734
2 M2 8.727 0.0031
3 M3 0.116 0.734
4 M4 0.116 0.734
5 M5 0.707 0.4004
6 M6 8.727 0.0031
7 M7 8.727 0.0031
8 M8 8.727 0.0031
9 M9 0.116 0.734
10 M10 8.727 0.0031
11 M11 0.468 0.4941
12 M12 0.349 0.5545
13 M13 0.349 0.5545
14 M14 0.116 0.734
15 M15 0.349 0.5545
16 M16 0.116 0.734
17 M17 0.232 0.6301
18 M18 0.232 0.6301
19 M19 8.727 0.0031
20 M20 0.116 0.734
21 M21 8.727 0.0031
22 M22 8.727 0.0031
23 M23 4.857 0.0275
24 M24 0.116 0.734
25 M25 8.727 0.0031
26 M26 17.524 2.84E-05
27 M27 8.727 0.0031
28 M28 8.727 0.0031
29 M29 0.116 0.734
30 M30 17.524 2.84E-05
31 M31 8.727 0.0031
32 M32 1.738 0.1874
33 M33 17.722 2.56E-05
34 M34 8.433 0.0037
35 M35 1.074 0.3001
36 M36 1.323 0.25
37 M37 0.116 0.734
38 M38 0.232 0.6301
39 M39 35.33 2.78E-09
40 M40 0.116 0.734
41 M41 8.433 0.0037
42 M42 0.468 0.4941
43 M43 0.116 0.734
44 M44 0.232 0.6301
45 M45 0.116 0.734
46 M46 17.524 2.84E-05
47 M47 0.116 0.734
48 M48 10.46 0.0012
49 M49 17.524 2.84E-05
50 M50 0.116 0.734
51 M51 0.116 0.734
52 M52 0.116 0.734
53 M53 8.727 0.0031
54 M54 8.727 0.0031
55 M55 26.391 2.79E-07
56 M56 8.727 0.0031
57 M57 17.524 2.84E-05
58 M58 8.727 0.0031
59 M59 8.727 0.0031
60 M60 8.727 0.0031
61 M61 8.727 0.0031
62 M62 8.727 0.0031
63 M63 0.116 0.734
64 M64 8.727 0.0031
65 M65 8.727 0.0031
66 M66 8.727 0.0031
67 M67 8.727 0.0031
68 M68 8.727 0.0031
69 M69 8.727 0.0031
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Supplementary table 10. List of references with the number 
of patients reported in the study
Reference cited Patient sample used in the study
Coupry et al. 2002 60
Bartsch et al. 2002 10
Kalkhoven  et al. 2003 39
Bartsch et al. 2005 45
Udaka  et al. 2005 21
Roelfsema  et al. 2005 92
Bentivegna et al. 2006 31
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Supplementary fi gure 1. Representation of the distribution of nucleotide changes in the CREBBP gene of RSTS patients. Numbers in 
the yellow block represent exon mutations and blue blocks represent intron mutations. Numbers in the red and green blocks represent the 
missense and the sense/silent mutations, respectively, in each of the patients. 
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Supplementary fi gure 2. Primary sequences corresponding to the minimal human p300 and CREBBP HAT domains are aligned with 
the same and conserved residues highlighted in black and white, respectively.
